AbbVie Inc. (TSX:ABBV)

Market Cap	524.77B +19.9%
Revenue (ttm)	83.86B +8.6%
Net Income	5.79B -1.2%
EPS	3.24 -1.3%
Shares Out	n/a
PE Ratio	90.57
Forward PE	14.79
Dividend	0.95 (3.09%)
Ex-Dividend Date	Jan 16, 2026

Volume	166,217
Average Volume	11,750
Open	30.25
Previous Close	31.77
Day's Range	29.07 - 30.87
52-Week Range	23.68 - 34.48
Beta	n/a
RSI	44.38
Earnings Date	Feb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.23 billion, a decrease of -0.28%.

Financial numbers in USD